|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-10.20/-2.60
|
企业价值
9.56M
|
资产负债 |
每股账面净值
1.41
|
现金流量 |
现金流量率
--
|
损益表 |
收益
709.00K
|
每股收益
0.18
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/01 05:15 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty. |